2018
Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population
Dinan MA, Li Y, Reed SD, Sosa JA. Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population. Endocrine Practice 2018, 25: 31-42. PMID: 30383499, DOI: 10.4158/ep-2018-0253.Peer-Reviewed Original ResearchConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneThyroid-stimulating hormoneMultivariable analysisPatient populationUse of rhTSHLower inpatient costsMean outpatient costsDistant metastatic diseaseDifferentiated thyroid cancerEmergency department visitsRadioactive iodine administrationCancer patient populationSEER-Medicare dataCostly hospital staysTotal inpatient daysHealthcare Common Procedure Coding SystemTotal Medicare paymentsNumber of outpatientsMedicare patient populationPositron emission tomographySimilar overall costsRAI administrationHospital stayMultiple comorbiditiesReal-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.
Dinan M, Georgieva M, Shenolikar R, Scales C. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma. Journal Of Clinical Oncology 2018, 36: 415-415. DOI: 10.1200/jco.2018.36.6_suppl.415.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaMedicare patientsUrothelial carcinomaInitial chemotherapyPlatinum-doublet regimenAdvanced urothelial carcinomaDistant metastatic diseasePlatinum-containing chemotherapyReceipt of chemotherapyMetastatic bladder cancerYear of diagnosisCongestive heart failureGemcitabine/carboplatinGemcitabine/cisplatinUpper urinary tractCharacterized patientsDoublet chemotherapyNeoadjuvant chemotherapyDoublet regimenMetastatic diseaseMost patientsSystemic therapyHeart failureRenal diseaseComorbid conditions
2013
Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.
Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.Peer-Reviewed Original ResearchPalliative radiation therapyMetastatic prostate cancerProstate cancerRadiation therapyBony metastasesInclusion criteriaOutpatient facilitiesMedicare paymentsDistant metastatic diseaseTime of diagnosisPalliative radiation treatmentSEER-Medicare dataTreatment claimsStudy inclusion criteriaProstate cancer metastasisHealth care costsTotal Medicare paymentsAverage Medicare paymentsHealth care expendituresCarrier claimsPalliative radiationMetastatic diseasePalliative treatmentMedian ageMedian time